ルイジアナ州におけるCOPDの臨床試験
ルイジアナ州内の拠点で、COPDに関する9件の研究が参加者を募集しています。
ルイジアナ州内の都市
公式研究テキスト（英語）
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Ochsner LSU Health Shreveport - Academic Medical Center- Site Number : 8400083, Shreveport
- Care Access - Shreveport - Youree Drive- Site Number : 8400007, Shreveport
被験者募集中第3相
40歳〜80歳 · 全性別 · 2026/10/01更新 · NCT07190222Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Southern Clinical Research - Zachary- Site Number : 8400113, Zachary
被験者募集中第3相
40歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07190209A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Zachary
被験者募集中第2相
40歳以上 · 全性別 · 2026/09/09更新 · NCT07082738A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
- GSK Investigational Site, Lake Charles
被験者募集中第3相
40歳〜80歳 · 全性別 · 2026/09/09更新 · NCT07780669A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Southern Clinical Research, LLC, Zachary
被験者募集中第2/3相
35歳〜80歳 · 全性別 · 2026/08/31更新 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Lafayette
- Research Site, Monroe
- Research Site, Zachary
被験者募集中第3相
40歳〜80歳 · 全性別 · 2026/08/26更新 · NCT06283966STRIVE Post-Market Registry Study
- LSU Health Shreveport, Shreveport
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/03更新 · NCT04302272eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Lake Charles
- GSK Investigational Site, Shreveport
被験者募集中第3相
40歳〜75歳 · 全性別 · 2026/07/28更新 · NCT07177339Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Baton Rouge
- GSK Investigational Site, Lafayette
- GSK Investigational Site, Shreveport
被験者募集中第3相
40歳〜80歳 · 全性別 · 2026/04/09更新 · NCT06961214ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。